"Cladribine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
| Descriptor ID |
D017338
|
| MeSH Number(s) |
D03.633.100.759.590.138.300.200 D03.633.100.759.590.138.325.075 D13.570.230.229.075 D13.570.583.138.300.200 D13.570.583.138.325.075 D13.570.800.096.300.200
|
| Concept/Terms |
Cladribine- Cladribine
- 2-Chlorodeoxyadenosine
- 2-Chloro-2'-deoxyadenosine
- 2'-Deoxy-2-chloroadenosine
|
Below are MeSH descriptors whose meaning is more general than "Cladribine".
Below are MeSH descriptors whose meaning is more specific than "Cladribine".
This graph shows the total number of publications written about "Cladribine" by people in this website by year, and whether "Cladribine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cladribine" by people in Profiles.
-
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer. 2024 Oct 01; 130(19):3333-3343.
-
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma. 2024 Sep; 65(9):1325-1334.
-
ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget. 2024 Mar 14; 15:220-231.
-
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.
-
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 2023 02 15; 129(4):560-568.
-
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857.
-
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621.
-
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561.
-
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.
-
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021 04 15; 127(8):1186-1207.